1,009
Views
67
CrossRef citations to date
0
Altmetric
Original Articles

Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice

, , , ORCID Icon, , , ORCID Icon & ORCID Icon show all
Pages 436-442 | Received 17 May 2018, Accepted 06 Dec 2018, Published online: 15 Jan 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Igor Koturbash & Robert J Griffin. (2019) Harnessing epigenetics and metabolism to modulate tissue response to radiotherapy. International Journal of Radiation Biology 95:4, pages 379-381.
Read now

Articles from other publishers (66)

Douglas Adamoski, Marilia Meira Dias, Jose Edwin Neciosup Quesñay, Zhengyi Yang, Ievgeniia Zagoriy, Anna M. Steyer, Camila Tanimoto Rodrigues, Alliny Cristiny da Silva Bastos, Bianca Novaes da Silva, Renna Karoline Eloi Costa, Flávia Mayumi Odahara de Abreu, Zeyaul Islam, Alexandre Cassago, Marin Gerard van Heel, Sílvio Roberto Consonni, Simone Mattei, Julia Mahamid, Rodrigo Villares Portugal, Andre Luis Berteli Ambrosio & Sandra Martha Gomes Dias. (2023) Molecular mechanism of glutaminase activation through filamentation and the role of filaments in mitophagy protection. Nature Structural & Molecular Biology.
Crossref
Saverio Tardito & Craig MacKay. (2023) Rethinking our approach to cancer metabolism to deliver patient benefit. British Journal of Cancer 129:3, pages 406-415.
Crossref
Octavia-Laura Moldovan, Alexandra Sandulea, Ioana-Andreea Lungu, Șerban Andrei Gâz & Aura Rusu. (2023) Identification of Some Glutamic Acid Derivatives with Biological Potential by Computational Methods. Molecules 28:10, pages 4123.
Crossref
Srihari Shankar, Sarath Ramachandran, Nikhil Tulsian, Sridhar Radhakrishnan, Chacko Jobichen & J. Sivaraman. (2022) A novel allosteric site employs a conserved inhibition mechanism in human kidney‐type glutaminase. The FEBS Journal 290:9, pages 2437-2448.
Crossref
Abdullah A. Osman, Emre Arslan, Mason Bartels, Chieko Michikawa, Antje Lindemann, Katarzyna Tomczak, Wangjie Yu, Vlad Sandulache, Wencai Ma, Li Shen, Jing Wang, Anand K. Singh, Mitchell J. Frederick, Nakia D. Spencer, Jeffery Kovacs, Timothy Heffernan, William F. Symmans, Kunal Rai & Jeffrey N. Myers. (2023) Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 29:7, pages 1344-1359.
Crossref
Jonghwa Jin, Jun-Kyu Byun, Yeon-Kyung Choi & Keun-Gyu Park. (2023) Targeting glutamine metabolism as a therapeutic strategy for cancer. Experimental & Molecular Medicine 55:4, pages 706-715.
Crossref
Gautam Adhikary, Suruchi Shrestha, Warren Naselsky, John J. Newland, Xi Chen, Wen Xu, Ashkan Emadi, Joseph S. Friedberg & Richard L. Eckert. (2022) Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation. Molecular Carcinogenesis 62:4, pages 438-449.
Crossref
N. S. Finiuk, I. V. Drapak, B. S. Zimenkovsky & R. S. Stoika. (2023) Study of the anticancer activity of N-(5-methyl-[1,3,4]thiadiazol-2-yl)-propionamide toward human tumor cells in vitro. Biopolymers and Cell 39:1, pages 33-41.
Crossref
Wei Zhao, Xumiao Jing, Tao Wang & Fengqiu Zhang. (2023) Glutamine Deprivation Synergizes the Anticancer Effects of Cold Atmospheric Plasma on Esophageal Cancer Cells. Molecules 28:3, pages 1461.
Crossref
Qianhua Feng, Yutong Hao, Shuaiqi Yang, Xiaomin Yuan, Jing Chen, Yuying Mei, Lanlan Liu, Junbiao Chang, Zhenzhong Zhang & Lei Wang. (2023) A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy. Acta Pharmaceutica Sinica B 13:2, pages 775-786.
Crossref
Rong Zhou, Hoon Choi, Jianbo Cao, Austin Pantel, Mamta Gupta, Hsiaoju S. Lee & David Mankoff. (2023) 18 F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models . Journal of Nuclear Medicine 64:1, pages 131-136.
Crossref
Annika Dhawan, Phillip M. Pifer, Vlad C. Sandulache & Heath D. Skinner. (2022) Metabolic targeting, immunotherapy and radiation in locally advanced non-small cell lung cancer: Where do we go from here?. Frontiers in Oncology 12.
Crossref
Thuy-Tien T Nguyen, William P Katt & Richard A Cerione. (2022) Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies. Future Drug Discovery 4:4.
Crossref
Ryan S. Alden, Mohammad Zahid Kamran, Bassel A. Bashjawish & Brittany A. Simone. (2022) Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. Frontiers in Oncology 12.
Crossref
Jasmin Sponagel, Jill K. Jones, Cheryl Frankfater, Shanshan Zhang, Olivia Tung, Kevin Cho, Kelsey L. Tinkum, Hannah Gass, Elena Nunez, Douglas R. Spitz, Prakash Chinnaiyan, Jacob Schaefer, Gary J. Patti, Maya S. Graham, Audrey Mauguen, Milan Grkovski, Mark P. Dunphy, Simone Krebs, Jingqin Luo, Joshua B. Rubin & Joseph E. Ippolito. (2022) Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment. Med 3:11, pages 792-811.e12.
Crossref
Michalina Kryszczuk & Oksana Kowalczuk. (2022) Significance of NRF2 in physiological and pathological conditions an comprehensive review. Archives of Biochemistry and Biophysics 730, pages 109417.
Crossref
Tengfang Gong, Changbing Zheng, Xidan Ou, Jie Zheng, Jiayi Yu, Shuyu Chen, Yehui Duan & Wei Liu. (2022) Glutamine metabolism in cancers: Targeting the oxidative homeostasis. Frontiers in Oncology 12.
Crossref
Philippe Icard, Luca Simula, Ludovic Fournel, Karen Leroy, Audrey Lupo, Diane Damotte, Marie Christine Charpentier, Catherine Durdux, Mauro Loi, Olivier Schussler, Guillaume Chassagnon, Antoine Coquerel, Hubert Lincet, Vincent De Pauw & Marco Alifano. (2022) The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications. Drug Resistance Updates 63, pages 100852.
Crossref
Shiqi Nong, Yuran Qian, Tingyue Zhang, Xueyan Zhou, Yuhao Wei, Xiaomeng Yin & Xuelei Ma. (2022) Mechanism and application of nonessential amino acid deprivation associated with tumor therapy. MedComm – Future Medicine 1:1.
Crossref
Anh Nhat Tran. (2022) Targeting glutamine addiction in meningioma. Neuro-Oncology 24:4, pages 569-570.
Crossref
Feng Wu, Yaqian Du, Jiani Yang, Boyang Shao, Zhensheng Mi, Yuanfei Yao, Ying Cui, Fei He, Yanqiao Zhang & Piaoping Yang. (2022) Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death. ACS Nano 16:3, pages 3647-3663.
Crossref
Wei Meng, Joshua D. Palmer, Michael Siedow, Saikh Jaharul Haque & Arnab Chakravarti. (2022) Overcoming Radiation Resistance in Gliomas by Targeting Metabolism and DNA Repair Pathways. International Journal of Molecular Sciences 23:4, pages 2246.
Crossref
Enyu Tang, Siyang Liu, Zhiming Zhang, Rixin Zhang, Dejing Huang, Tong Gao, Tianze Zhang & Guangquan Xu. (2022) Therapeutic Potential of Glutamine Pathway in Lung Cancer. Frontiers in Oncology 11.
Crossref
Graham H. Read, Justine Bailleul, Erina Vlashi & Aparna H. Kesarwala. (2021) Metabolic response to radiation therapy in cancer. Molecular Carcinogenesis 61:2, pages 200-224.
Crossref
Tejveer Singh, Arun Sidram Kharat, Brijesh Rathi & Dhruv Kumar. 2022. Autophagy and Metabolism. Autophagy and Metabolism 239 280 .
Soumen Bera, Amit Verma, Anant N. Bhatt & Bilikere S. Dwarakanath. 2022. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 1969 2003 .
Yang Liu, Ruyi Xu, Huiyao Gu, Enfan Zhang, Jianwei Qu, Wen Cao, Xi Huang, Haimeng Yan, Jingsong He & Zhen Cai. (2021) Metabolic reprogramming in macrophage responses. Biomarker Research 9:1.
Crossref
Ronghui Yang, Zihao Guo, Yiliang Zhao, Lingdi Ma, Binghui Li & Chuanzhen Yang. (2021) Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase. Cell Death Discovery 7:1.
Crossref
Jasmeet Kaur & Shalmoli Bhattacharyya. (2021) Cancer Stem Cells: Metabolic Characterization for Targeted Cancer Therapy. Frontiers in Oncology 11.
Crossref
Gina M. DeNicola & David B. Shackelford. (2021) Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. Cold Spring Harbor Perspectives in Medicine 11:11, pages a037838.
Crossref
May Elbanna, Nayela N. Chowdhury, Ryan Rhome & Melissa L. Fishel. (2021) Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Frontiers in Oncology 11.
Crossref
Miriam Sánchez-Ortega, Ana Clara Carrera & Antonio Garrido. (2021) Role of NRF2 in Lung Cancer. Cells 10:8, pages 1879.
Crossref
Aboli Bhingarkar, Hima V. Vangapandu, Sanjay Rathod, Keito Hoshitsuki & Christian A. Fernandez. (2021) Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias. Frontiers in Oncology 11.
Crossref
Philippe Icard, Mauro Loi, Zherui Wu, Antonin Ginguay, Hubert Lincet, Edouard Robin, Antoine Coquerel, Diana Berzan, Ludovic Fournel & Marco Alifano. (2021) Metabolic Strategies for Inhibiting Cancer Development. Advances in Nutrition 12:4, pages 1461-1480.
Crossref
Octavia-Laura Moldovan, Aura Rusu, Corneliu Tanase & Camil-Eugen Vari. (2021) Glutamate - A multifaceted molecule: Endogenous neurotransmitter, controversial food additive, design compound for anti-cancer drugs. A critical appraisal. Food and Chemical Toxicology 153, pages 112290.
Crossref
Johann Matschke, Safa Larafa & Verena Jendrossek. (2021) Metabolic reprograming of antioxidant defense: a precision medicine perspective for radiotherapy of lung cancer?. Biochemical Society Transactions 49:3, pages 1265-1277.
Crossref
Austin C. Boese & Sumin Kang. (2021) Mitochondrial metabolism-mediated redox regulation in cancer progression. Redox Biology 42, pages 101870.
Crossref
Marike W. van Gisbergen, Emma Zwilling & Ludwig J. Dubois. (2021) Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio. Frontiers in Oncology 11.
Crossref
Zin W. Myint, Ramon C. Sun, Patrick J. Hensley, Andrew C. James, Peng Wang, Stephen E. Strup, Robert J. McDonald, Donglin Yan, William H. St. Clair & Derek B. Allison. (2021) Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters. Cancers 13:9, pages 2157.
Crossref
Henrique J. Cardoso, Marília I. Figueira, Cátia V. Vaz, Tiago M. A. Carvalho, Luís A. Brás, Patrícia A. Madureira, Paulo J. Oliveira, Vilma A. Sardão & Sílvia Socorro. (2021) Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation. Cellular Oncology 44:2, pages 385-403.
Crossref
Diana C. Contreras Healey, Jacqueline Y. Cephus, Sierra M. Barone, Nowrin U. Chowdhury, Debolanle O. Dahunsi, Matthew Z. Madden, Xiang Ye, Xuemei Yu, Kellen Olszewski, Kirsten Young, Valerie A. Gerriets, Peter J. Siska, Ryszard Dworski, Jonathan Hemler, Jason W. Locasale, Masha V. Poyurovsky, R. Stokes PeeblesJr.Jr., Jonathan M. Irish, Dawn C. Newcomb & Jeffrey C. Rathmell. (2021) Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation. The Journal of Immunology 206:6, pages 1127-1139.
Crossref
Piyada Sitthideatphaiboon, Ana Galan-Cobo, Marcelo V. Negrao, Xiao Qu, Alissa Poteete, Fahao Zhang, Diane D. Liu, Whitney E. Lewis, Haley N. Kemp, Jeff Lewis, Waree Rinsurongkawong, Uma Giri, J. Jack Lee, Jianjun Zhang, Jack A. Roth, Stephen Swisher & John V. Heymach. (2021) STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition . Clinical Cancer Research 27:6, pages 1720-1733.
Crossref
Meng Xia, Xuena Li, Yao Diao, Bulin Du & Yaming Li. (2021) Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. Translational Oncology 14:1, pages 100920.
Crossref
Yang Liu, Fengchao Lang & Chunzhang Yang. (2021) NRF2 in human neoplasm: Cancer biology and potential therapeutic target. Pharmacology & Therapeutics 217, pages 107664.
Crossref
Soumen Bera, Amit Verma, Anant N. Bhatt & Bilikere S. Dwarakanath. 2020. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects 1 35 .
Anna Mukha & Anna Dubrovska. (2020) Metabolic Targeting of Cancer Stem Cells. Frontiers in Oncology 10.
Crossref
Lindsey R. Conroy, Pawel Lorkiewicz, Liqing He, Xinmin Yin, Xiang Zhang, Shesh N. Rai & Brian F. Clem. (2020) Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells. Cancer Cell International 20:1.
Crossref
Michael S. Binkley, Young-Jun Jeon, Monica Nesselbush, Everett J. Moding, Barzin Y. Nabet, Diego Almanza, Christian Kunder, Henning Stehr, Christopher H. Yoo, Siyeon Rhee, Michael Xiang, Jacob J. Chabon, Emily Hamilton, David M. Kurtz, Linda Gojenola, Susie Grant Owen, Ryan B. Ko, June Ho Shin, Peter G. Maxim, Natalie S. Lui, Leah M. Backhus, Mark F. Berry, Joseph B. Shrager, Kavitha J. Ramchandran, Sukhmani K. Padda, Millie Das, Joel W. Neal, Heather A. Wakelee, Ash A. Alizadeh, Billy W. LooJrJr & Maximilian Diehn. (2020) KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition . Cancer Discovery 10:12, pages 1826-1841.
Crossref
Ramachandran Rashmi, Kay Jayachandran, Jin Zhang, Vishnu Menon, Naoshad Muhammad, Michael Zahner, Fiona Ruiz, Sisi Zhang, Kevin Cho, Yuting Wang, Xiaojing Huang, Yi Huang, Michael L. McCormick, Buck E. Rogers, Douglas R. Spitz, Gary J. Patti & Julie K. Schwarz. (2020) Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers. Molecular Cancer Therapeutics 19:12, pages 2465-2475.
Crossref
Huang-Yu Yang, Chao-Yi Wu, Jia-Jin Chen & Tao-Han Lee. (2020) Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences 21:23, pages 8993.
Crossref
Jiangang Zhao, Xu Lin, Di Meng, Liping Zeng, Runzhou Zhuang, Sha Huang, Wang Lv & Jian Hu. (2020) Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer. Frontiers in Oncology 10.
Crossref
Michael J. Soth, Kang Le, Maria Emilia Di Francesco, Matthew M. Hamilton, Gang Liu, Jason P. Burke, Chris L. Carroll, Jeffrey J. Kovacs, Jennifer P. Bardenhagen, Christopher A. Bristow, Mario Cardozo, Barbara Czako, Elisa de Stanchina, Ningping Feng, Jill R. Garvey, Jason P. Gay, Mary K. Geck Do, Jennifer Greer, Michelle Han, Angela Harris, Zachary Herrera, Sha Huang, Virginia Giuliani, Yongying Jiang, Sarah B. Johnson, Troy A. Johnson, Zhijun Kang, Paul G. Leonard, Zhen Liu, Timothy McAfoos, Meredith Miller, Pietro Morlacchi, Robert A. Mullinax, Wylie S. Palmer, Jihai Pang, Norma Rogers, Charles M. Rudin, Hannah E. Shepard, Nakia D. Spencer, Jay Theroff, Qi Wu, Alan Xu, Ju Anne Yau, Giulio Draetta, Carlo Toniatti, Timothy P. Heffernan & Philip Jones. (2020) Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. Journal of Medicinal Chemistry 63:21, pages 12957-12977.
Crossref
Martin Kery & Ioanna Papandreou. (2020) Emerging strategies to target cancer metabolism and improve radiation therapy outcomes. The British Journal of Radiology 93:1115, pages 20200067.
Crossref
Dunxin Shen, Laken Kruger, Tyler Deatherage & Travis T. Denton. (2020) Synthesis of α-Ketoglutaramic acid. Analytical Biochemistry 607, pages 113862.
Crossref
Monika Szeliga. (2020) Thiadiazole derivatives as anticancer agents. Pharmacological Reports 72:5, pages 1079-1100.
Crossref
Rosa Maria Pascale, Diego Francesco Calvisi, Maria Maddalena Simile, Claudio Francesco Feo & Francesco Feo. (2020) The Warburg Effect 97 Years after Its Discovery. Cancers 12:10, pages 2819.
Crossref
Atsushi Tanabe & Hiroeki Sahara. (2020) The Metabolic Heterogeneity and Flexibility of Cancer Stem Cells. Cancers 12:10, pages 2780.
Crossref
L. A. Braun, E. E. Varpetyan, G. A. Zav’yalov, F. V. Kulikov, V. E. Marievskii, D. A. Tyul’ganova, A. O. Shishnenko, D. S. Stepanova & N. L. Shimanovskii. (2020) Metabolic Enzymes: New Targets for the Design of Antitumor Drugs. Pharmaceutical Chemistry Journal 54:6, pages 547-554.
Crossref
Luca Frattaruolo, Matteo Brindisi, Rosita Curcio, Federica Marra, Vincenza Dolce & Anna Rita Cappello. (2020) Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment. International Journal of Molecular Sciences 21:17, pages 6014.
Crossref
José M. Matés, José A. Campos-Sandoval, Juan de los Santos-Jiménez & Javier Márquez. (2020) Glutaminases regulate glutathione and oxidative stress in cancer. Archives of Toxicology 94:8, pages 2603-2623.
Crossref
Nai-Yun Sun & Muh-Hwa Yang. (2020) Metabolic Reprogramming and Epithelial-Mesenchymal Plasticity: Opportunities and Challenges for Cancer Therapy. Frontiers in Oncology 10.
Crossref
Katharina Koch, Rudolf Hartmann, Julia Tsiampali, Constanze Uhlmann, Ann-Christin Nickel, Xiaoling He, Marcel A. Kamp, Michael Sabel, Roger A. Barker, Hans-Jakob Steiger, Daniel Hänggi, Dieter Willbold, Jaroslaw Maciaczyk & Ulf D. Kahlert. (2020) A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity. Cell Death Discovery 6:1.
Crossref
David A. Bader & Sean E. McGuire. (2020) Tumour metabolism and its unique properties in prostate adenocarcinoma. Nature Reviews Urology 17:4, pages 214-231.
Crossref
Johannes F. Fahrmann, Jody V. Vykoukal & Edwin J. Ostrin. (2020) Amino Acid Oncometabolism and Immunomodulation of the Tumor Microenvironment in Lung Cancer. Frontiers in Oncology 10.
Crossref
Pearl Lee, Dania Malik, Nicholas Perkons, Peiwei Huangyang, Sanika Khare, Seth Rhoades, Yao-Yu Gong, Michelle Burrows, Jennifer M. Finan, Itzhak Nissim, Terence P. F. Gade, Aalim M. Weljie & M. Celeste Simon. (2020) Targeting glutamine metabolism slows soft tissue sarcoma growth. Nature Communications 11:1.
Crossref
Daniel Wahl, Michael Petronek, Rashmi Ramachandran, John Floberg, Bryan G. Allen & Julie K. Schwarz. 2020. Molecular Targeted Radiosensitizers. Molecular Targeted Radiosensitizers 219 263 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.